A new tool that makes it possible to adapt treatment for patients with cardiogenic shock has been discovered
Cardiogenic shock is a possible complication of serious heart attack involving an associated mortality rate of approximately 50% of all cases. The combination of this new tool with existing methods renders precise and patient-specific decision-making possible. The research is being led by Dr. Antoni Bayés at Germans Trias and the Proteomics Unit of the CRG and UPF, under Dr. Eduard Sabidó